Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer and other hormonally driven cancers, today announced that Jodie Morrison, president and chief executive officer, will present an overview of the company and the interim Phase 2 data on its lead prostate cancer drug candidate galeterone at the 34th Annual Cowen Health Care Conference on Monday, March 3, 2014 at 2:00 p.m. (ET) in Boston.
Help employers find you! Check out all the jobs and post your resume.
